Trastuzumab emtansine activates endogenous tumor suppression through Mdm2, Mdm4 and ST13.

Mechanism of action for antibody drug conjugates has not yet been completely elucidated. We demonstrate here by measurement of total transcription induction of endogenous tumor suppression by trastuzumab emtansine, T-DM1. Tumor suppression engaged by T-DM1 included ST13 and the p53-associated Mdm2 and Mdm4.

Authors

Shahan Mamoor (ORCID: https://orcid.org/0000-0003-4150-0936)

Publication Details

Journal: Zenodo (CERN European Organization for Nuclear Research)
Published: 2026-10-29
DOI: https://doi.org/10.5281/zenodo.23771870
Primary Topic: Cancer-related Molecular Pathways
Type: preprint

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

preprint

Trastuzumab emtansine activates endogenous tumor suppression through Mdm2, Mdm4 and ST13.

Shahan Mamoor

Oct 29, 2026

4 links

Zenodo (CERN European Organization for Nuclear Research)

Cancer-related Molecular Pathways

preprint

Trastuzumab emtansine activates endogenous tumor suppression through Mdm2, Mdm4 and ST13.

Shahan Mamoor

October 29, 2026preprint en

Abstract

Zenodo (CERN European Organization for Nuclear Research)

Good health and well-being

Cancer-related Molecular Pathways

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon

Trastuzumab emtansine activates endogenous tumor suppression through Mdm2, Mdm4 and ST13. — Shahan Mamoor · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS